The tangled web of coronary risk factors
1Donner Laboratory, Molecular Medicine Research Program, University of California, Berkeley 94720.
Insights
Specific low-density lipoprotein (LDL) subclasses, like LDL-III, and reduced high-density lipoprotein 2 (HDL2) indicate a high-risk state for coronary artery disease due to linked metabolic factors.
Area of Science:
- Cardiovascular Medicine
- Lipidology
- Metabolic Syndrome
Background:
- Epidemiologic, genetic, and pathophysiologic studies confirm low-density lipoproteins (LDLs) role in coronary artery disease (CAD).
- Standard LDL cholesterol measurement includes components with varying contributions to CAD.
- Certain LDL subclasses, like intermediate-density lipoproteins (IDLs) and lipoprotein (a), are highly atherogenic.
Purpose of the Study:
- To investigate the significance of specific LDL subclasses, particularly LDL-III, in CAD risk.
- To explore the association between LDL-III levels and various metabolic and hormonal factors.
- To understand the implications of a lipoprotein profile characterized by increased LDL-III and decreased HDL2.
Main Methods:
- Analysis of epidemiologic, genetic, and pathophysiologic data.
- Characterization of LDL subclasses, including small, dense LDL-III.
- Correlation of lipoprotein levels with metabolic factors such as gender, menopausal status, adiposity, triglycerides, apolipoprotein B, and HDL subclasses.
Main Results:
- Small, dense LDL-III is associated with increased CAD risk.
- LDL-III levels correlate with male gender, postmenopause, abdominal adiposity, elevated triglycerides, increased apolipoprotein B, and reduced HDL2.
- These factors are often linked to insulin resistance and hyperinsulinemia.
Conclusions:
- A lipoprotein profile with increased LDL-III and decreased HDL2 signifies a high-risk metabolic state for CAD.
- The complex interplay of genetic and environmental factors contributes to CAD susceptibility.
- Identifying specific high-risk lipoprotein profiles aids in understanding and managing CAD risk.
Abstract:
Although epidemiologic, genetic, and pathophysiologic studies have shown that low-density lipoproteins (LDLs) are involved in the development of coronary artery disease, the standard measurement of LDL cholesterol comprises a number of separate components that may contribute in different ways to the disease process. Some of these components appear to be of particular pathologic importance. Intermediate-density lipoproteins (IDLs) and lipoprotein (a) are highly atherogenic species that each normally account for up to 10% to 15% total LDL cholesterol but may be disproportionately elevated in pathologic states and may therefore contribute disproportionately to coronary disease risk in certain patients. Recently, another subclass of LDL, characterized by relatively small particle size and increased density, also has been found to be associated with relatively increased risk of coronary disease. Furthermore, levels of this subclass, designated LDL-III, are linked to a number of interrelated hormonal and metabolic factors, each of which have also been associated with risk of coronary artery disease. These include male gender, postmenopause, abdominal adiposity, elevated triglyceride levels, increased levels of apolipoprotein B, and reductions in high-density lipoproteins (HDLs), particularly in the HDL2 subclass. Other studies have demonstrated that many of these factors are also commonly associated with relative insulin resistance and hyperinsulinemia. Thus, a lipoprotein profile characterized by a relative increase in LDL-III and a reduction in HDL2 is indicative of a constellation of metabolic features that defines a high-risk state and that makes it extremely difficult to single out one or more factors that are most directly involved in the disease process. Combinations of genetic and environmental factors acting on this "tangled web" of risk factors may account for much of the variation in coronary disease susceptibility found in the general population.
More Related Videos
Related Concept Videos
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis I: Introduction
![Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F3777.jpg&w=3840&q=50)

